Targeting GAS2 not only significantly inhibited CML cell proliferation but also enhanced the sensitivity of these cells to Imatinib, a commonly used therapeutic agent in CML treatment. This evidence concerns the gene GAS2 and chronic myelogenous leukemia, BCR-ABL1 positive.